A multicenter 1H-MRS study of the medial temporal lobe in AD and MCI

Objective: The need for biological markers of Alzheimer disease (AD) is constantly increasing. Proton magnetic resonance spectroscopy (1H-MRS) studies have provided consistent evidence for a reduction of the neuronal marker N-acetylaspartate (NAA) in patients with AD. Within the German Competence Network on Dementia, we conducted a 1H-MRS study in patients with mild dementia and mild cognitive impairment (MCI) at four sites to investigate the multicenter feasibility of 1H-MRS. Methods: In total, 130 patients with dementia (98 AD, 32 non-AD), 136 subjects with MCI (70 of AD type, 66 of non-AD type), and 45 unimpaired control subjects were included. Single-volume 1H-MRS of the left medial temporal lobe was performed at long and short echo times. Metabolites were quantified and metabolic ratios were determined. Results: We found a significant reduction of NAA concentration in patients with AD as compared to healthy volunteers and compared to patients with MCI of AD type. NAA/Cr (creatine/phosphocreatine) was also lower in patients with AD compared to control subjects. NAA, choline compounds, and Cr were lower in patients with AD compared to patients with non-AD dementia. Conclusions: We demonstrated the multicenter feasibility of proton magnetic resonance spectroscopy (1H-MRS) of the medial temporal lobe in mild dementia and mild cognitive impairment, which is a prerequisite for the application of 1H-MRS in large-scale clinical trials. Since the concentration measures of the metabolites are adjusted for brain tissue volume, these findings are indicators of biochemical pathology beyond brain atrophy.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  Kevin M Bradley,et al.  Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. , 2002, Brain : a journal of neurology.

[3]  F. Jessen,et al.  Treatment monitoring and response prediction with proton MR spectroscopy in AD , 2006, Neurology.

[4]  Clifford R. Jack,et al.  Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease , 2007, Neurobiology of Aging.

[5]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[6]  A. Mackinnon,et al.  Do cognitive complaints either predict future cognitive decline or reflect past cognitive decline? A longitudinal study of an elderly community sample , 1997, Psychological Medicine.

[7]  N. Fayed,et al.  Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. , 2005, The American journal of psychiatry.

[8]  D. Graveron-Demilly,et al.  Java-based graphical user interface for the MRUI quantitation package , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[9]  Harald Hampel,et al.  A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe , 2006, European Radiology.

[10]  M N Rossor,et al.  MRS shows abnormalities before symptoms in familial Alzheimer disease , 2006, Neurology.

[11]  Christopher Clark,et al.  Disease-modifying therapies for Alzheimer disease , 2007, Neurology.

[12]  F. Jessen,et al.  Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients , 2001, Neurology.

[13]  S. Chantal,et al.  Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease , 2004, Brain Research.

[14]  E G Tangalos,et al.  1H MR spectroscopy in common dementias , 2004, Neurology.

[15]  K Yaffe,et al.  Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD , 2003, Neurology.

[16]  N. Fayed,et al.  Changes in Metabolite Ratios after Treatment with Rivastigmine in Alzheimer’s Disease , 2006, CNS drugs.

[17]  J. Moffett,et al.  N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology , 2007, Progress in Neurobiology.

[18]  Vanhamme,et al.  Improved method for accurate and efficient quantification of MRS data with use of prior knowledge , 1997, Journal of magnetic resonance.

[19]  F. Jessen,et al.  A Comparative Study of the Different N-Acetylaspartate Measures of the Medial Temporal Lobe in Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.

[20]  Xin Yu,et al.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. , 2003, The American journal of psychiatry.

[21]  N. Schuff,et al.  Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD , 2002, Neurology.

[22]  K. Kantarci.  1H magnetic resonance spectroscopy in dementia. , 2007, The British journal of radiology.

[23]  D van Ormondt,et al.  Cramér–Rao bounds: an evaluation tool for quantitation , 2001, NMR in biomedicine.

[24]  B. L. Miller,et al.  Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients , 2005, Neurology.